



OncoK9 Clinical Use Cases

OncoK9 is recommended as an **annual screening test** for dogs at higher risk of cancer¹⁴



Beagle
Bernese Mountain Dog
Boxer
Flat-Coated Retriever
French Bulldog
German Shepherd
Golden Retriever
Labrador Retriever
Rhodesian Ridgeback
Rottweiler
Siberian Husky
Giant Breeds (including Great Dane, Irish Wolfhound, Mastiff, and Scottish Deerhound)

OncoK9 is recommended as an **aid-in-diagnosis test** for dogs in which cancer is suspected



AntechDiagnostics.com/OncoK9/



OncoK9 Test Workflow

- | | |
|--|---|
| <p>i  Blood Collection at Clinic</p> <p>ii  Shipment to Lab</p> <p>iii  DNA Extraction & Sequencing</p> <p>iv  Bioinformatics Analysis</p> | <p>v  PetDx Results Review (Lab Director & PetDx Veterinary Team)</p> <p>vi  Veterinarian Receives OncoK9 Report</p> <p>viii  Veterinarian Communicates OncoK9 Test Results & Next Steps to Pet Owner</p> |
|--|---|

Easy Integration Into Your Practice


How do I order OncoK9 tests?

Order OncoK9 through AVD or by completing our Submission Form, writing "OncoK9" into the "Other Test" section. Search "OncoK9" in the Directory of Services or use the **OncoK9 Test Code: S14493**.

How do I receive OncoK9 support?

Check out our Veterinary Support site at support.petdx.com for a list of FAQs and resources or to submit customer support requests. Specialist consultations are available to discuss cancer treatment options. Contact **AVD Customer Service** at:

HK: +852 2371 0080 | MY +852 9118 7047 | SG: +65 6291 5412




To learn about the rapidly growing number of patients that have benefited from OncoK9, please visit petdx.science/case-studies.

Early Cancer Detection in Dogs Starts with a Simple Blood Draw

6 Million New Cancer Cases Per Year in Dogs

Older dogs and certain breeds have a higher lifetime risk of cancer and/or have a higher risk of being diagnosed at an earlier age. Cancer in dogs is often diagnosed at an advanced stage, when treatment options are limited, and chances of long-term control or cure are low.

People get mammograms, colonoscopies, and other cancer screening tests to help detect cancer early. Now, our dogs have **OncoK9**, a cancer screening test developed specifically for them, ushering in a new era of preventive care for pets.




Cancer Is by Far the **#1 Cause of Death in Dogs**



Lifetime Risk of Cancer: **1 in 3 Dogs**


For a list of references 1-16 used in this document, please visit OncoK9.info/Veterinary-Overview

Cancer Is a Disease of the Genome¹



Each cell in a dog's body contains billions of DNA "letters" that make up the dog's genome. Cancer develops as a result of the successive accumulation of genomic alterations (DNA mutations) over time. All cells release DNA fragments into the bloodstream. DNA released from cancer cells contains specific genomic alterations associated with cancer that can be detected by liquid biopsy with the **OncoK9** test.

OncoK9 indicates whether cancer is currently present in the body; it does not indicate risk for future cancer development.



OncoK9: The Liquid Biopsy Test for Dogs

As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients.

<p>Simple Blood Draw</p> <ul style="list-style-type: none"> Can be drawn in clinic same day No fasting required No sample processing required in clinic Validated in cancer-diagnosed dogs and in cancer-free dogs with a range of other medical conditions 	<p>Multi-Cancer Coverage</p> <ul style="list-style-type: none"> Proven ability to detect 30 distinct cancer types, with high detection rates in many of the most common cancers in dogs Cancer signal origin prediction in a subset of hematological malignancies 	<p>Cutting-Edge Technology</p> <ul style="list-style-type: none"> Uses next-generation sequencing (NGS) technology No refrigeration or freezing of the sample; shipped overnight at ambient temperature Low false positive rate 	<p>Early Detection</p> <ul style="list-style-type: none"> Identifies cancer signal in DNA extracted from a blood sample Earlier cancer detection before the onset of clinical signs may be possible
--	--	---	--

OncoK9 Multi-Cancer Detection

List of cancer types detected in the CANDID (CANcer Detection in Dogs) study by histologic type and/or anatomic location
3 of the most aggressive canine cancers shown in pink | **8 of the most common canine cancers shown in bold**

A Abdominal Cavity Anal Sac Adenocarcinoma	H Heart Base Hemangiosarcoma Histiocytic Sarcoma	M Malignant Melanoma Mammary Gland Carcinoma Mast Cell Tumor	S Salivary Gland Skin Soft Tissue Sarcoma Stomach
B Bile Duct Bone, Osteosarcoma Brain	K Kidney	N Nasal Cavity and Paranasal Sinuses	T Thyroid Transmissible Venereal Tumor
C Chondrosarcoma	L Leukemia, Acute Lymphoid (ALL) Leukemia, Chronic Lymphoid (CLL)	O Oral Cavity	U Urinary Bladder / Urethra
E Ear Canal	P Liver Lung Lymphoma, Indolent Lymphoma, Intermediate to Large Cell	P Peripheral Nerve Sheath	

OncoK9 Test Performance

Cancer Type (Canine)	Screening Method	Detection Rate	False Positive Rate*
3 of the most aggressive canine cancers	OncoK9	85%	1.5%
8 of the most common canine cancers	OncoK9	62%	1.5%
All cancers in CANDID Study	OncoK9	55%	1.5%

*False Positive Rate of 1.5% corresponds to a Specificity of 98.5%

Performance of Commonly Used Human Cancer Screening Tests²⁻¹⁵

OncoK9 provides cancer screening performance that meets and, in many cases, exceeds established human standards

Cancer Type (Human)	Screening Method	Detection Rate	False Positive Rate*
Breast	Digital mammogram	77 - 95%	3 - 6%
Cervical	Pap test	68 - 94%	25 - 74%
Prostate	PSA level**	21 - 86%	9 - 67%
Lung	Low dose CT	59 - 100%	1 - 74%
Colon	Stool DNA-based test***	92 - 93%	13 - 15%

* False Positive Rate = 1 - Specificity ** PSA level (4ng/mL) *** Cologuard

OncoK9 Test Interpretation: Probability of Cancer or Cancer-Free

Clinical use case	Intended use population	Probability that a patient with an OncoK9 Cancer Signal Detected result has cancer (PPV)	Probability that a patient with an OncoK9 Cancer Signal Not Detected result does not have cancer (NPV)
Screening	Higher risk of cancer due to age and/or breed	76 - 80%	95 - 96%
Aid-in-diagnosis	Cancer suspected based on clinical presentation	94 - 97%	68 - 84%

Estimated ranges for positive predictive value (PPV) and negative predictive value (NPV) calculated using a test sensitivity of 54.7% and specificity of 98.5% (based on 0-10% prior probability in the screening use case, and 50-50% prior probability in the aid-in-diagnosis use case)